![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/spacer.gif)
852A A synthetic imidazoquinoline Toll-like receptor 7 (TLR7) agonist with immunostimulating and potential antitumor activities. TLR7 agonist 852A binds to and activates TLR7, thereby stimulating plasmacytoid dendritic cells (pDC) through the TLR7-MyD88-dependent signaling pathway. Activation of pDC results in secretion of interferon alpha, the production of proimflammatory cytokines, the upregulation of co-stimulatory molecules, and enhanced T and B-cell stimulatory responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/spacer.gif)
Synonyms: | ![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/spacer.gif) | TLR7 agonist 852A Toll-like receptor agonist 852A | | ![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509150537im_/http://www.cancer.gov/images/spacer.gif) |